DOI: 10.12890/2025_005233

Metachronous occurrence of acute myeloid leukaemia in a case of neuroendocrine tumour

Authors

  • Abhinav Menon Department of Medical Oncology, Aster Medcity, Kochi, India
  • Dilip Harindran Vallathol Department of Medical Oncology, Aster Medcity, Kochi, India
  • Deepak Charles Department of Hemato-Oncology, Aster Medcity, Kochi, India
  • Shagos Nair Department of Nuclear Medicine, Aster Medcity, Kochi, India
  • Karthika Kundil Veetil Department of Pathology, Aster MIMS, Kozhikode, India
  • Ashok S. Komaranchath Department of Medical Oncology, Aster Medcity, Kochi, India
  • Arun R. Warrier Department of Medical Oncology, Aster Medcity, Kochi, India

abhinav.amenon@gmail.com

Keywords

Neuroendocrine neoplasm, peptide receptor radionuclide therapy, acute myeloid leukemia, dual malignancy

Abstract

Haematological neoplasms are rare in patients undergoing peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasms, though the long-term effects on bone marrow function remain an area of interest. We report the case of an elderly woman diagnosed with a pancreatic neuroendocrine tumour (pNET) who developed acute myeloid leukaemia (AML) while receiving PRRT. She was treated with a non-chemotherapy regimen of azacitidine and venetoclax, resulting in remission of both AML and the neuroendocrine tumour. This case highlights the potential risk of secondary haematological malignancies following PRRT and underscores the efficacy of a non-intensive therapeutic approach in managing AML in this context.

View the entire article

Downloads

References

  1. Bourguignon MH, Gisone PA, Perez MR, Michelin S, Dubner D, Giorgio MD et al. Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response. Eur J Nucl Med Mol Imaging 2005;32:229–246.
  2. Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C et al. Dosimetry for treatment with radiolabelled somatostatin analogues: a review. Q J Nucl Med Mol Imaging 2010;54:37–51.
  3. Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2018;59:452–458.
  4. Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol 2020;6:1086–1092.
  5. Joseph R, McRee AJ, Mathews S, Zeidner JF. Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET). Leuk Lymphoma 2019;60:2793–2797.

Published

2025-03-10

Issue

Vol. 12 No. 4 (2025)

Categories

How to Cite

1.
Menon A, Harindran Vallathol D, Charles D, Nair S, Kundil Veetil K, Komaranchath AS, et al. Metachronous occurrence of acute myeloid leukaemia in a case of neuroendocrine tumour. EJCRIM [Internet]. 2025 Mar. 10 [cited 2026 Nov. 3];12(4). Available from: https://ejcrim.com/index.php/ejcrim/article/view/5233